Phaseline

Companies › Contineum Therapeutics

Contineum Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PIPE-791–Phase 2Idiopathic Pulmonary FibrosisMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07284459PIPE-791Phase 2Idiopathic Pulmonary FibrosisRespiratoryMay 2028

From the company's SEC filings

Cash and short-term investments of $244m on 2026-09-30; operating cash outflow about $52m a year; runway about 56 months at that burn, to Jun 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Incannex Healthcare Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.